ATAnnika Taithongchai

Annika Taithongchai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annika Taithongchai has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The use of topical vaginal estrogens in postpartum women: A systematic review

    by Aysha Waheed, Annika Taithongchai, Dudley Robinson

    Introduction: Topical vaginal estrogens have been used in the management of postmenopausal vulvovaginal atrophy for some time, locally reintroducing exogenous estrogens to the estrogen‐receptive tissues of the female urogenital tract following a decline in systemic levels. The postpartum period is similarly a state of relative estrogen depletion due to the antagonistic effect from raised prolactin levels throughout pregnancy and lactation; this is thought to contribute to post‐delivery pelvic floor dysfunction and vaginal atrophy. Given the similar etiology, there may be a role for topical vaginal estrogens in postpartum women. Material and Methods: A systematic review was performed evaluating the use of topical vaginal estrogens in postpartum women. This was performed as per PRISMA guidelines, with articles screened from online databases from their inception to October 2025. Results: Three studies were identified that met the inclusion criteria, including a total of 85 women. Two studies focused on the molecular and cellular composition of tissues from postpartum women using topical vaginal estrogens, and one double‐blind randomized placebo‐controlled trial primarily evaluated postpartum atrophy in the presence and absence of vaginal estrogens. Tissues exposed to estrogen appeared to have increased cellular proliferation, while the Vulval Assessment Score (VuAS), a patient‐subjective validated scoring system for vaginal atrophy, was found to be lower in those using vaginal estrogen cream for 12 weeks. No statistically significant difference in bladder, bowel, or sexual function was noted. No serious adverse outcomes were reported, and the use of vaginal estrogens appeared acceptable to women. Conclusions: There is a paucity of data currently available regarding the use of topical vaginal estrogens in the post‐partum period. Although likely safe for use, further evidence is required to be able to make firm conclusions about their efficacy for postpartum vaginal atrophy, and further high‐quality trials are required in the future.


  • Open Access

    How Can We Improve the Assessment and Indifferent Outcomes From Pelvic Organ Prolapse Management From Conservative and Surgical Therapies? ICI‐RS 2025

    by Rohna Kearney, Adrian Wagg, Wendy Bower, Chris Chapple, Vik Khullar, Dudley Robinson, Annika Taithongchai, Philip Toozs Hobson, Alan Wein, Paul Abrams

    Introduction: Pelvic organ prolapse is a common condition and many women seek surgical treatment for prolapse symptoms. However, recurrence of prolapse after surgical treatment is common. A think tank was held at ICI‐RS 2025 to discuss how the assessment and indifferent results from conservative and surgical management can be improved. Methods: Data were collected and presented on identification of women at risk of prolapse recurrence after surgery, understanding patient goals and expectations, optimising lifestyle interventions, pelvic floor muscle training, pessary management, and surgical care. Discussions identified knowledge gaps and proposed research studies that could advance knowledge to improve treatment outcomes. Results: There is insufficient information to understand the assessment of prolapse treatment outcomes; examination findings do not necessarily correlate with symptoms. Further research is needed to understand if patient‐reported goal attainment is superior to patient‐reported outcome measures, including measures of patient satisfaction. There is insufficient information on the value of lifestyle adjustments and pelvic floor muscle training as prehabilitation to improve surgical outcomes. The place of pessary management in an optimally integrated prolapse treatment pathway is unclear and the role that pessaries may have in anatomical modelling of prolapse is not fully understood. Further research into adjuncts to improve native tissue repair as alternatives to polypropylene mesh is needed to optimise surgical outcome. Conclusion: Further research into understanding what represents treatment, cure, and optimising conservative and surgical treatments is of high priority to improve pelvic organ prolapse treatment outcomes. The utility of preoperative rehabilitation requires investigation. Developing an optimised pessary care pathway and continued surgical innovation are required to ensure progress in reducing prolapse symptom recurrence.


  • Open Access

    Current practice of colposuspension in the United Kingdom: Results of a national survey

    by Kar Yee Lor, Annika Taithongchai, George Araklitis, Aysha Waheed, Rayan Mohamed‐Ahmed, Angie Rantell, Dudley Robinson

    Introduction: Colposuspension procedures have increased in the UK following the 2018 suspension of vaginal mesh for stress urinary incontinence. However, significant variation exists in preoperative assessment, patient selection, surgical approach, and postoperative care. This survey aims to explore current national practice. Material and Methods: A questionnaire was distributed to members of the British Society of Urogynaecology (BSUG) and the British Association of Urological Surgeons (BAUS). Results: Fifty‐three clinicians responded; most were gynecologists with a special interest in urogynecology (60%) or urogynecology subspecialists (34%). Response rates were 12% (51/442) among BSUG members and 20 for 2%. Most surgeons (85%) perform preoperative urodynamics in all patients, while 15% restrict testing to women with mixed symptoms. Almost all (98.1%) would treat detrusor overactivity or symptomatic overactive bladder prior to offering colposuspension. Forty‐five percent will perform colposuspension at any functional or maximum cytometric capacity; others use cutoffs of >400 mL (19%), >300 mL (26%) or >200 mL (10%). Fifty‐five percent reported a BMI limit of <35, while 19% have no limit. Most surgeons favored an open approach (58%), followed by laparoscopic (38%) and robotic (4%). Sutures were usually suspended tension‐free (75%) using Ethibond (53%) or PDS (40%), with 72% consenting for the use of non‐absorbable sutures. For open colposuspension, two sutures bilaterally were preferred (49%), followed by three (40%) and four (11%). Laparoscopic or robotic procedures were mostly intra‐peritoneal (89%), with surgeons placing two sutures bilaterally (88%) and tying their knots extracorporeally (75%). Thirty‐nine percent close the peritoneum over their sutures. Routine check cystoscopy was performed by 60%. Postoperatively, indwelling urinary catheters are mostly left on free drainage (69%); 17% always use a suprapubic catheter and 4% preferred clean intermittent self‐catheterization. Trial without catheter is most commonly attempted on Day 1 post‐colposuspension (74%), with variable voiding criteria and acceptable post‐void residuals. Conclusion: This national survey highlights marked heterogeneity in UK colposuspension practice. There is a need for comparative studies and national consensus on core technical steps to ensure safety and favorable long‐term outcomes.


  • Open Access

    Do We Have the Evidence to Produce Tools to Enable the Identification and Personalization of Management of Women's Pelvic Floor Health Disorders Through the Perinatal and Perimenopausal Periods? ICI‐RS 2024

    by Rohna Kearney, Stefano Salvatore, Vik Khullar, Christopher Chapple, Annika Taithongchai, Alan Uren, Paul Abrams, Alan Wein

    Introduction: There is an increasing recognition of the impact of ageing on pelvic floor health and the consequences in populations with rising proportions of women over the age of 65 years. A think tank was held at the ICI‐RS 2024 to discuss the evidence to support the personalisation of women's pelvic floor health during the perinatal and perimenopausal period.Methods: Data was collected and presented on the evidence to support the development of tools to personalise pelvic floor health care. Epidemiological, imaging, patient‐reported outcomes, and evidence of tool development questionnaires were discussed. The current evidence and research gaps for potential intervention to prevent the pelvic floor disorders of pelvic organ prolapse, overactive bladder, urinary incontinence and faecal incontinence during the perinatal and perimenopasual time periods were discussed and identified.Results: Epidemiological studies highlight that vaginal delivery and in particular operative vaginal delivery is the single biggest modifiable risk factor for the future development of pelvic floor dysfunction. The oestrogen depletion resulting from the perimenopause and menopause can lead to the development of Genitourinary syndrome of menopause (GSM) which is associated with the risk of developing pelvic floor dysfunction. Ultrasound is a useful technique for assessing the pelvic floor and has been used to assess bladder neck mobility, distensibility of the puborectalis muscle and the striated urethral sphincter volume antenatally with some studies reporting a correlation between these measurements and the need for Caesarean section and development of postpartum stress urinary incontinence. Further studies are needed to standardise these measurements. There are no patient reported outcome questionnaires validated for use in the perinatal and postmenopausal period. The UR‐ choice tool has been developed to counsel women on the risk of postpartum pelvic floor disorders occurring. However, further evaluation in larger numbers is required.Conclusion: There is significant interest in developing tools to counsel women on the risks of developing pelvic floor dysfunction post partum and after the menopause. Further evaluation of the UR‐choice tool was considered a research priority. The timepoint of cervical screening for research into interventions such as pelvic floor health education, lifestyle optimisation and perimenopausal vaginal oestrogen supplementation was identified.


  • Open Access

    Prolapse in pregnancy

    by Annika Taithongchai, Dudley Robinson


  • Are We Able to Optimize Outcomes and Predict Complications in Pelvic Floor Surgery With a Better Understanding of Hormonal, Microbial and Other Factors? A Report From the ICI‐RS 2024

    by A. Taithongchai, F. Reid, E. Finazzi Agro, E. Rosato, D. Bianchi, M. Serati, A. S. Da Silva, I. Giarenis, D. Robinson, P. Abrams

    Introduction: Pelvic organ prolapse (POP) is a common condition, affecting women worldwide and is known to have a significant impact on Health Related Quality of Life (HRQoL). Although there are various treatment options available, including pelvic floor muscle training and support pessaries, many women opt for or require surgery, with a lifetime risk of needing surgery of 12%–19%. As with any operation, this does not come without its complications and the reoperation rate following POP surgery is up to 36%.This International Consultation on Incontinence–Research Society (ICI‐RS) report aims to look at the different factors which may play a role in objective and subjective outcomes following pelvic floor surgery and to summarize the evidence and uncertainties regarding prediction of POP surgical outcomes, how to optimize them and the tools available to predict them. Research question proposals to further this field have been highlighted.Methods: At ICI‐RS 2024, the evidence for predicting the outcomes from POP surgery and methods to optimize outcomes were discussed and presented in this paper.Results: There are many reasons why POP surgery may fail, such as variations in lifestyle and occupation, persistent constipation, failure in the perineal body, connective tissue types or the shape of the pelvis. There may also be inherent conditions of the vagina, such as hormonal or microbial features. The literature lacks evidence about the potential use of advanced statistical modeling or supervised machine learning in the development of management plans for patients with POP. Furthermore, future research is needed to determine the role of UDS in the preoperative evaluation of POP patients.Conclusions: High‐quality powered studies are required to assess optimization for long‐term outcomes of pelvic surgery and then, once these are well established, and possible interventions are elucidated, prediction modeling can have a real impact clinically.


  • Should hormone replacement therapy (any route of administration) be considered in all postmenopausal women with lower urinary tract symptoms? Report from the ICI‐RS 2023

    by Annika Taithongchai, Rayan Mohamed‐Ahmed, Sanjay Sinha, William Gibson, Ilias Giarenis, Dudley Robinson, Paul Abrams

    Aims: This International Consultation on Incontinence‐Research Society report aims to summarize the evidence and uncertainties regarding the use of hormone replacement therapy by any route in the management of lower urinary tract symptoms (LUTS) including recurrent urinary tract infections (rUTI), with a review of special considerations for the elderly. Research question proposals to further this field have been highlighted.Methods: An overview of the existing evidence, guidelines, and consensus regarding the use of topical or systemic estrogens in the management of LUTS.Results: There are currently evidence and recommendations to offer topical estrogens to postmenopausal women with overactive bladder symptoms as well as postmenopausal women with rUTIs. Systemic estrogens however have been shown in a meta‐analysis to have a negative effect on LUTS and, therefore are not currently recommended.Conclusions: Although available evidence and recommendations exist for the use of topical estrogens, few women are commenced on these in primary care. There remain large gaps still within our knowledge of the use of estrogens within the management of LUTS, particularly on when it should be commenced, the length of time treatment should be continued for, and barriers to prescribing.


  • Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women

    by Annika Taithongchai, Eugenie E Johnson, Sharif I Ismail, Evelyn Barron-Millar, Ashleigh Kernohan, Ranee Thakar

    Background Pelvic organ prolapse (POP) is the descent of a woman's uterus, bladder, or rectum into the vagina. It affects 50% of women over 50 years old who have given birth to at least one child, and recognised risk factors are older age, higher number of births, and higher body mass index. This review assesses the effects of oestrogen therapy, alone or in combination with other treatments, on POP in postmenopausal women. Objectives To assess the benefits and harms of local and systemic oestrogen therapy in the management of pelvic organ prolapse symptoms in postmenopausal women, and to summarise the principal findings of relevant economic evaluations. Search methods We searched the Cochrane Incontinence Specialised Register (up to 20 June 2022), which includes CENTRAL, MEDLINE, two trials registers, and handsearching of journals and conference proceedings. We also checked the reference lists of relevant articles for additional studies. Selection criteria We included randomised controlled trials (RCTs), quasi‐RCTs, multi‐arm RCTs, and cross‐over RCTs that evaluated the effects of oestrogen therapy (alone or in combination with other treatments) versus placebo, no treatment, or other interventions in postmenopausal women with any grade of POP. Data collection and analysis Two review authors independently extracted data from the included trials using prespecified outcome measures and a piloted extraction form. The same review authors independently assessed the risk of bias of eligible trials using Cochrane's risk of bias tool. Had data allowed, we would have created summary of findings tables for our main outcome measures and assessed the certainty of the evidence using GRADE. Main results We identified 14 studies including a total of 1002 women. In general, studies were at high risk of bias in terms of blinding of participants and personnel, and there were also some concerns about selective reporting. Owing to insufficient data for the outcomes of interest, we were unable to perform our planned subgroup analyses (systemic versus topical oestrogen, parous versus nulliparous women, women with versus without a uterus). No studies assessed the effects of oestrogen therapy alone versus no treatment, placebo, pelvic floor muscle training, devices such as vaginal pessaries, or surgery. However, we did identify three studies that assessed oestrogen therapy in conjunction with vaginal pessaries versus vaginal pessaries alone and 11 studies that assessed oestrogen therapy in conjunction with surgery versus surgery alone. Authors' conclusions There was insufficient evidence from RCTs to draw any solid conclusions on the benefits or harms of oestrogen therapy for managing POP symptoms in postmenopausal women. Topical oestrogen in conjunction with pessaries was associated with fewer adverse vaginal events compared with pessaries alone, and topical oestrogen in conjunction with surgery was associated with reduced postoperative urinary tract infections compared with surgery alone; however, these findings should be interpreted with caution, as the studies that contributed data varied substantially in their design. There is a need for larger studies on the effectiveness and cost‐effectiveness of oestrogen therapy, used alone or in conjunction with pelvic floor muscle training, vaginal pessaries, or surgery, for the management of POP. These studies should measure outcomes in the medium and long term.


  • Oestrogen therapy for treating pelvic organ prolapse in postmenopausal women

    by Annika Taithongchai, Sharif I Ismail, Eugenie Johnson, Evelyn Barron Millar, Ashleigh Kernohan, Ranee Thakar

    This is a protocol for a Cochrane Review (intervention). The objectives are as follows: